Free Account Opening + AMC Free Demat
Loading...

Emcure Pharma IPO Review Summary from brokers and analysts

Review By Apply May Apply Neutral Avoid Not Rated
Count 15 3 0 0 0
% 83.33 16.67 0.00 0.00 0.00

Emcure Pharma IPO Capital Market Rating

The Captial Market (CapitalMarket.com) rating for Emcure Pharma IPO is 45. Their analysis recommends May subscribe for the IPO.

Reviewer Rating Score Rating
Capital Market 45 May subscribe

Emcure Pharma IPO Review by Dilip Davda (Apply)

[Dilip Davda]  The company is one of the leading pharma company having niche products and serving global markets. It marked growth in its top lines, but bottom line posted declining trends due to higher interest and depreciation costs. Based on FY24 earnings, the issue appears fully priced. Reduction in debt post IPO will improved its bottom line commensurately. Investors may park funds for the medium to longer term. Read detail review...

Emcure Pharma IPO Peer Comparison

Emcure Pharmaceuticals Limited peer comparison with similar listed entities. (As on March 31, 2024)

Company NameEPS (Basic)EPS (Diluted)NAV (per share) (Rs)P/E (x)RoNW (%)P/BV RatioFinancial statements
Emcure Pharmaceuticals Limited27.5427.54163.2221.27Consolidated
Dr. Reddy's Laboratories Limited335.22335.591,693.7517.9319.743.54Consolidated
Cipla Ltd.51.0551.01330.7830.1015.434.64Consolidated
Alkem Laboratories Ltd150.19150.19862.4633.8617.415.90Consolidated
Torrent Pharmaceuticals Ltd.48.9448.94202.5757.7424.1513.95Consolidated
Mankind Pharma Limited47.7547.68233.7345.3020.439.24Consolidated
Abbott India Ltd.565.28565.281,740.7147.4332.4815.40Consolidated
J. B. Chemicals & Pharmaceuticals Limited35.6634.85188.3750.4918.909.34Consolidated

The financial information for Emcure Pharma is based on the Restated Consolidated Financial Statements as of and for the financial year ended March 31, 2024. The financial information for listed industry peers mentioned above, sourced from the audited financial statements of the respective companies for the financial year ended March 31, 2024, is on a consolidated basis (except for Abbott India Limited, where financial information is available only on a standalone basis) and is submitted to the Stock Exchanges. 

Notes:

  1. Basic and Diluted EPS for peers are sourced from the audited financial statements for the relevant year
  2. The P/E Ratio has been computed based on the closing market price of equity shares on BSE Limited on June 21, 2024 divided by the Diluted EPS
  3. For listed peers, RoNW is computed as profit attributable to company owners divided by Total Equity attributable to the owners of the Company as on March 31, 2024.
  4. Net Asset Value ("NAV") is computed as the closing net worth divided by the equity shares outstanding as on March 31, 2024.

Emcure Pharma IPO Review by Members

Emcure Pharma IPO Reviews, analysis and views by popular members. Read Emcure Pharmaceuticals Limited IPO reviews by retail investors to find recommended ipo to buy.

Post Recommendation Manage Your IPO Reviews

Emcure Pharma IPO Review Summary by Members

Review By Apply May Apply Neutral Avoid
Count 2 2 0 0
% 50.00 50.00 0.00 0.00
Clear Search
Member Review
Ankit Dhakad

Apply for Listing Gain at Cut-off Price

Apply for good listing gains as well as long term. The company has great brand value and financials.

I Like It. 1

July 3, 2024 3:11:35 PM
Jitendra pareek

Apply for Listing Gain at Upper Price Band

Good fundamentals and post ipo debt will be paid so valuation is reasonable

July 1, 2024 9:07:22 PM
Dhanvantri

May Apply for Long Term at Upper Price Band

Borrowing 2000 crores much higher HIV Monopoly pharma co Price Band much higher nothing left for listing gain May Apply

June 29, 2024 10:37:17 AM
Professōr
Top Contributor Top Contributor (600+ Posts, 200+ Likes)

May Apply for Short Term at Cut-off Price

No superb listing gains expected , decent returns will be there

June 28, 2024 10:16:19 AM

Post Recommendation Manage Recommendations

Note:

  • The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
  • We reserve the right to remove any objectionable post without providing a reason.